TargetBeta
ESR1
estrogen receptor 1 · also ER, NR3A1, Era, ER-alpha · Estrogen receptors
15 programs in company-led studies act on ESR1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (12 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Fulvestrantrule | AstraZeneca | phase 4 | 305 running | – | ChEMBL |
| Tamoxifenrule | AstraZeneca | phase 4 | 214 running | – | ChEMBL |
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 701 running | – | ChEMBL |
| Estradiolrule | Novo Nordisk | phase 4 | 691 running | – | ChEMBL |
| Clomiphenerule | Hamad Medical | phase 4 | 31 running | – | ChEMBL |
| giredestrant | Hoffmann-La Roche | phase 3 | 1712 running | – | a judged reading |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 1310 running | – | the company's pipeline |
| camizestrantrule | AstraZeneca | phase 3 | 189 running | – | NCIt |
| vepdegestrantrule | Pfizer | phase 3 | 206 running | – | NCIt |
| Imlunestrantrule | Eli Lilly | phase 3 | 126 running | – | NCIt |
| elacestrantrule | Menarini Group | phase 3 | 125 running | – | NCIt |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 54 running | – | the studies' text |
| palazestrantrule | Olema Pharmaceuticals | phase 3 | 43 running | – | NCIt |
| taragarestrantrule | InventisBio | phase 3 | 51 running | – | NCIt |
| Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117 | Johnson & Johnson | phase 1 | 11 running | – | a judged reading |
Conditions their studies are in
- Breast Neoplasms, 12 programs
- Hot Flashes, 3 programs
- Neoplasm Metastasis, 3 programs
- Endometrial Neoplasms, 2 programs
- Neoplasms, 2 programs
- Ovarian Neoplasms, 2 programs
- Anovulation, 1 program
- Atrophic Vaginitis, 1 program
- Carcinoma, Intraductal, Noninfiltrating, 1 program
- Diabetes Mellitus, Type 2, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026elacestrant · Menarini Group · phase 3 · NCT05596409
- Nov 30, 2026taragarestrant · InventisBio · phase 3 · NCT06954961
- Dec 2026Tamoxifen · AstraZeneca · phase 4 · NCT05780567
- Dec 4, 2026vepdegestrant · Pfizer · phase 3 · NCT07231991
- Feb 2027HRS-8080 · Jiangsu HengRui Medicine · phase 3 · NCT07876596
- Feb 26, 2027Fulvestrant · AstraZeneca · phase 4 · NCT05262400
- Apr 20, 2027camizestrant · AstraZeneca · phase 3 · NCT05774951
- May 31, 2027Estradiol · Novo Nordisk · phase 4 · NCT07794150
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.